Intellia Therapeutics Inc (NASDAQ: NTLA) started the day on Wednesday, with a price decrease of -2.72% at $8.24, before settling in for the price of $8.47 at the close. Taking a more long-term approach, NTLA posted a 52-week range of $5.90-$28.25.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -20.04%. Meanwhile, its Annual Earning per share during the time was -20.04%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 23.31%. This publicly-traded company’s shares outstanding now amounts to $115.79 million, simultaneously with a float of $109.90 million. The organization now has a market capitalization sitting at $954.44 million. At the time of writing, stock’s 50-day Moving Average stood at $16.77, while the 200-day Moving Average is $11.49.
Intellia Therapeutics Inc (NTLA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Intellia Therapeutics Inc’s current insider ownership accounts for 5.12%, in contrast to 86.20% institutional ownership. According to the most recent insider trade that took place on Oct 01 ’25, this organization’s EVP, Chief Scientific Officer sold 31 shares at the rate of 17.38, making the entire transaction reach 539 in total value, affecting insider ownership by 105,184. Preceding that transaction, on Oct 01 ’25, Company’s VP, Chief Accounting Officer sold 1,871 for 17.38, making the whole transaction’s value amount to 32,518. This particular insider is now the holder of 55,266 in total.
Intellia Therapeutics Inc (NTLA) Earnings and Revenue Records
Intellia Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 23.31% and is forecasted to reach -3.52 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 29.78% through the next 5 years, which can be compared against the -20.04% growth it accomplished over the previous five years trading on the market.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Let’s observe the current performance indicators for Intellia Therapeutics Inc (NTLA). It’s Quick Ratio in the last reported quarter now stands at 6.21. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 16.59.
In the same vein, NTLA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.27, a figure that is expected to reach -0.97 in the next quarter, and analysts are predicting that it will be -3.52 at the market close of one year from today.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
If we take a close look at the recent performances of Intellia Therapeutics Inc (NASDAQ: NTLA), its last 5-days Average volume was 6.43 million that shows progress from its year to date volume of 5.2 million. During the previous 9 days, stock’s Stochastic %D was recorded 3.62% While, its Average True Range was 23.84.
Raw Stochastic average of Intellia Therapeutics Inc (NTLA) in the period of the previous 100 days is set at 0.20%, which indicates a major fall in contrast to 0.73% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.97 that was lower than 1.13 volatility it exhibited in the past 100-days period.
